AstraZeneca PLC Q3 2025 Earnings Recap

AstraZeneca delivered strong results for the first nine months of 2025, with total revenue increasing by 11% and core EPS up 15%, supported by robust demand across its diverse portfolio and significant regulatory achievements.

Key Takeaways

• Achieved 31 regulatory approvals this year and positive results from 16 Phase III trials, underscoring strong pipeline momentum.
• Oncology franchise grew by 16%, while biopharmaceuticals and rare diseases increased by 8% and 6%, respectively, driven by newer product launches.
• Landmark agreement with the U.S. government will reduce prescription medicine costs while enhancing pricing clarity and protections for future innovations.
• Expansion of U.S. manufacturing capabilities, including a new facility in Virginia, supports long-term growth ambitions.
• Proposed harmonization of share listings will improve capital access and shareholder participation in AstraZeneca's future growth.